Contact

Funding

PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects. We want to smooth your path to progress. We blend the right funding with the right advice and the right people to give your idea the best chance of success.

PACE upcoming funding call: 2024 Diagnostic Innovations

Our second funding call for innovative early-stage diagnostics projects, will open on 26 September 2024. Applications must have the potential to reduce inappropriate antibiotic prescriptions, provide faster results that indicate which antimicrobial should be used and/or catalyse the move to personalised narrow-spectrum treatments, with projects expected to last up to two years, with total funding of up to £5 million across all funded projects. Expressions of interest (EOIs) can be submitted from 26 September. Full details on the call scope and application process will be provided when the call opens. 

Array

Seeking projects with the greatest potential

PACE is not just about grant funding; we offer a truly collaborative approach to project development and delivery. Those who secure funding will feel the wider value of a network of potential project partners and receive advice and guidance from some of the best in the field. And we’re there for the long run, so whether you move to the next stage of development or are not successful in securing a grant this time around, you can stay plugged into our community and continue to benefit from our expert ecosystem.

We are helping to create and advance an exciting and diverse pipeline of preclinical phase projects aimed at diagnosing and treating bacterial infections with high unmet need. Our first funding round (launched in October 2023) focused on early stage, novel antibacterial therapeutics. Learn more about the 2023: Antibacterial Therapeutics Funding Round here.

Our second funding round will open on September 26 2024.

Eligibility

 

  • Our funding is open to researchers in academia and small and medium enterprises (SMEs) worldwide, including consortia (large pharma partners permitted, but must cover own costs)​.
  • Applications should have a single lead applicant, however co-applicants are welcome.

Sign up to receive news and to be alerted when the 2024 Diagnostic Innovations call is open